GE Healthcare launches first 'next-generation' sequencing assay

GE Healthcare announced that Clarient Diagnostic Services, a GE Healthcare company, will begin offering a next-generation sequencing assay focused on solid tumor targets for use in clinical trials. This assay will empower researchers to perform prospective and retrospective analysis to better understand which patients will respond to particular therapies, to help stratify patient populations for ongoing clinical trials, and to aid early research efforts.

View Comments (0)